Tuesday, Dec 5, 2023 · SEC filings
What the smart money revealed on Dec 5
949 insider filings came in. We hid 149 planned (10b5-1) sellers and 552 people whose filings were routine, like grants and tax withholding.
3 insiders at Generation Bio (GBIO) bought $747K of stock
Roles: Director. Several insiders buying in the same few days is rare.
Verve Therapeutics (VERV) Director Krishna Yeshwant bought $18M
1.8M shares on the open market. Not a grant or an option exercise.
Shoe Carnival (SHOE) Chairman of the Board Wayne Weaver bought $5.2M
206,500 shares on the open market. Not a grant or an option exercise.
Akero Therapeutics (AKRO) Director G. Walmsley Graham bought $1.69M
100,000 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 4 checked quarters beat the typical stock 6 months later.
Pulse Biosciences (PLSE) Director Robert Duggan bought $414K
45,600 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 6 checked quarters beat the typical stock 6 months later.
Palo Alto Networks (PANW) EVP Lee Klarich sold $12.9M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 185,217 shares directly.
Donnelley Financial Solutions (DFIN) Director Jeffrey Jacobowitz sold $12.2M
Not marked as a planned 10b5-1 sale. Sold 8% of the shares they held directly. Still holds 2.49M shares.
Marqeta (MQ) Chief Product and Technology Officer Randall Kern sold $332K
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 37 more real buys
Show 155 more real sales
13F season
Holdings as of Sep 30, 2023 were due Nov 14
40 funds have filed. 40 filed for the quarter before.
Biggest real insider buys, Nov 29–Dec 5
Open-market buys by officers and directors, filed in the 7 days up to Dec 5.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.